Analyst Price Targets — VRCA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 18, 2025 8:41 am | Kemp Dolliver | Loop Capital Markets | $17.00 | $8.05 | StreetInsider | Brookline Capital Markets Upgrades Verrica Pharmaceuticals (VRCA) to Buy |
| May 14, 2024 9:35 am | Glen Santangelo | Jefferies | $12.00 | $11.28 | StreetInsider | Verrica Pharmaceuticals (VRCA) PT Raised to $12 at Jefferies |
| May 14, 2024 6:51 am | Oren Livnat | H.C. Wainwright | $14.00 | $9.56 | StreetInsider | Verrica Pharmaceuticals (VRCA) PT Raised to $14 at H.C. Wainwright |
| July 25, 2023 1:03 pm | Serge Belanger | Needham | $10.00 | $5.32 | Benzinga | Verrica's Ycanth Unlikely to Face Near-Term Competition, Analyst Upgrades Stock On FDA Approval |
Latest News for VRCA
- Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan - - Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan, including common warts - WEST CHESTER, Pa.
– Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan –
WEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference.
WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 4th Annual BioConnect…
Verrica Pharmaceuticals NASDAQ: VRCA reported higher first-quarter revenue and record demand for its molluscum contagiosum treatment YCANTH, while outlining progress on late-stage development programs in common warts and basal cell carcinoma.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VRCA.
U.S. House Trading
No House trades found for VRCA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.